PP_1170x120_10-25-21

The Biosimilars Council

The Biosimilars Council applauds reintroduction of the bipartisan BIOSIM Act

The Biosimilars Council applauds reintroduction of the bipartisan BIOSIM Act

WASHINGTON — The Biosimilars Council, representing leading developers of biosimilar medicines, strongly supports the reintroduction, and encourages swift passage, of the bipartisan BIOSIM Act (HR 2815). This bill is an important step toward giving Americans greater access to lifesaving, affordable medicines. Christine Simmon, executive director of the Biosimilars Council, said, Every day, biosimilars help patients

FDA proposes suffix for biosimilar product names

FDA proposes suffix for biosimilar product names

WASHINGTON — Early feedback on the Food and Drug Administration’s proposal on naming conventions for biosimilars shows a mixed response. Late late week, the FDA published draft guidance recommending that reference biologic products and biosimilars have nonproprietary names that share a core drug substance name and an FDA-designated suffix unique for each product. For interchangeable